Top

Published in:

Open Access 01-12-2021 | Metastasis | Research article

New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients

Authors: Jun Yamamura, Shunji Kamigaki, Junya Fujita, Hiroki Osato, Hironobu Manabe, Yumiko Tanaka, Wataru Shinzaki, Yukihiko Hashimoto, Yoshifumi Komoike

Published in: BMC Cancer | Issue 1/2021

Abstract

Background

The initial therapeutic strategy for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer is based on the first metastatic site; however, little evidence is available regarding the influence of metastatic distribution patterns of first metastatic sites on prognosis. In this study, we aimed to identify the metastatic distribution patterns of first metastatic sites that significantly correlate with survival after recurrence.

Methods

We performed a retrospective review of records from 271 patients with recurrent metastatic HR+/HER2- breast cancer diagnosed between January 2000 and December 2015. We assessed survival after recurrence according to the metastatic distribution patterns of the first metastatic sites and identified significant prognostic factors among patients with single and multiple metastases.

Results

Prognosis was significantly better in patients with a single metastasis than in those with multiple metastases (median overall survival after recurrence: 5.86 years vs. 2.50 years, respectively, p < 0.001). No metastatic organ site with single metastasis was significantly associated with prognostic outcome, although single metastasis with diffuse lesions was an independent risk factor for worse prognosis (HR: 3.641; 95% CI: 1.856–7.141) and more easily progressing to multiple metastases (p = 0.002). Multiple metastases, including liver metastasis (HR: 3.145; 95% CI: 1.802–5.495) or brain metastasis (HR: 3.289; 95% CI: 1.355–7.937), were regarded as significant independent poor prognostic factors; however, multiple metastases not involving liver or brain metastasis were not significantly related to prognosis after recurrence.

Conclusions

Single metastases with diffuse lesions could more easily disseminate systemically and progress to multiple metastases, leading to a poor prognosis similar to multiple metastases. Our findings indicate that the reconsideration of the determinant factors of therapeutic strategies for first recurrence in HR+/HER2- breast cancer may be needed.

National Cancer Institute Surveillance, Epidemiology, and End Results Program. Cancer statistics: Cancer Stat Facts: Female Breast Cancer. National Cancer Institute; 2019. http://seer.cancer.gov/statfacts/html/breast.html. Accessed 2 Oct 2019

Hortobagyi GN, de la Garza SJ, Pritchard K, Amadori D, Haidinger R, Hudis CA, et al. The global breast cancer burden: variations in epidemiology and survival. Clin Breast Cancer. 2005;6(5):391–401. https://doi.org/10.3816/CBC.2005.n.043.CrossRefPubMed

Giuliani J, Bonetti A. Trends in survival for patients with metastatic breast cancer: is survival improving. Tumori. 2015;101(4):347–52. https://doi.org/10.5301/tj.5000301.CrossRefPubMed

Chung CT, Carlson RW. Goals and objectives in the management of metastatic breast cancer. Oncologist. 2003;8(6):514–20. https://doi.org/10.1634/theoncologist.8-6-514.CrossRefPubMed

Harb WA. Management of patients with hormone receptor-positive breast cancer with visceral disease: challenges and treatment options. Cancer Manag Res. 2015;7:37–46. https://doi.org/10.2147/CMAR.S72592.CrossRefPubMedPubMedCentral

Lobbezoo DJ, van Kampen RJ, Voogd AC, Dercksen MW, van den Berkmortel F, Smilde TJ, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–14. https://doi.org/10.1007/s10549-013-2711-y.CrossRefPubMed

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology (NCCN guidelines®) with NCCN evidence blocks™. 2019. https://www.nccn.org/EvidenceBlocks/. Accessed 8 Oct 2019.

Schnipper L, Davidson N, Wollins D, Blayney DW, Dicker AP, Ganz PA, et al. Updating the American Society of Clinical Oncology value framework: revisions and reflections in response to comments received. J Clin Oncol. 2016;34(24):2925–34. https://doi.org/10.1200/JCO.2016.68.2518.CrossRefPubMed

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Ann Oncol. 2018;29(8):1634–57. https://doi.org/10.1093/annonc/mdy192.CrossRef

10.

Le Saux O, Lardy-Cleaud A, Frank S, Debled M, Cottu PH, Pistilli B, et al. Assessment of the efficacy of successive endocrine therapies in hormone receptor-positive and HER2-negative metastatic breast cancer: a real-life multicentre national study. Eur J Cancer. 2019;118:131–41. https://doi.org/10.1016/j.ejca.2019.06.014.CrossRefPubMed

11.

Yamamura J, Kamigaki S, Tsujie M, Fujita J, Osato H, Higashi C, et al. Response to first-line recurrence treatment influences survival in hormone receptor-positive, HER2-negative breast cancer: a multicenter study. In Vivo. 2019;33(1):281–7. https://doi.org/10.21873/invivo.11473.CrossRefPubMedPubMedCentral

12.

Bonotto M, Gerratana L, Di Maio M, De Angelis C, Cinausero M, Moroso S, et al. Chemotherapy versus endocrine therapy as first-line treatment in patients with luminal-like HER2-negative metastatic breast cancer: a propensity score analysis. Breast. 2017;31:114–20. https://doi.org/10.1016/j.breast.2016.10.021.CrossRefPubMed

13.

Xie J, Hao Y, Li N, Lin PL, Ohashi E, Koo V, et al. Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US. Exp Hematol Oncol. 2015;4(1):31. https://doi.org/10.1186/s40164-015-0023-0.CrossRefPubMedPubMedCentral

14.

Rogoz B, Houzé de l’Aulnoit A, Duhamel A, Houzé de l’Aulnoit D. Thirty-year trends of survival and time-varying effects of prognostic factors in patients with metastatic breast cancer-a single institution experience. Clin Breast Cancer. 2018;18(3):246–53. https://doi.org/10.1016/j.clbc.2017.08.012.CrossRefPubMed

15.

Tsuji W, Teramukai S, Ueno M, Toi M, Inamoto T. Prognostic factors for survival after first recurrence in breast cancer: a retrospective analysis of 252 recurrent cases at a single institution. Breast Cancer. 2014;21(1):86–95. https://doi.org/10.1007/s12282-012-0358-x.CrossRefPubMed

16.

Jung SY, Rosenzweig M, Sereika SM, Linkov F, Brufsky A, Weissfeld JL. Factors associated with mortality after breast cancer metastasis. Cancer Causes Control. 2012;23(1):103–12. https://doi.org/10.1007/s10552-011-9859-8.CrossRefPubMed

17.

Largillier R, Ferrero JM, Doyen J, Barriere J, Namer M, Mari V, et al. Prognostic factors in 1,038 women with metastatic breast cancer. Ann Oncol. 2008;19(12):2012–9. https://doi.org/10.1093/annonc/mdn424.CrossRefPubMedPubMedCentral

18.

Andre F, Slimane K, Bachelot T, Dunant A, Namer M, Barrelier A, et al. Breast cancer with synchronous metastases: trends in survival during a 14-year period. J Clin Oncol. 2004;22(16):3302–8. https://doi.org/10.1200/JCO.2004.08.095.CrossRefPubMed

19.

Watanabe J, Hayashi T, Tadokoro Y, Nishimura S, Takahashi K. Clinical pattern of primary systemic therapy and outcomes of estrogen receptor-positive, HER2-negative metastatic breast cancer: a review of a single institution. Breast Cancer Res Treat. 2017;166(3):911–7. https://doi.org/10.1007/s10549-017-4478-z.CrossRefPubMed

20.

Llombart-Cussac A, Pivot X, Biganzoli L, Cortes-Funes H, Pritchard KI, Pierga JY, et al. A prognostic factor index for overall survival in patients receiving first-line chemotherapy for HER2-negative advanced breast cancer: an analysis of the ATHENA trial. Breast. 2014;23(5):656–62. https://doi.org/10.1016/j.breast.2014.06.017.CrossRefPubMed

21.

Cazzaniga M, Pronzato P, Leto di Priolo SL, De Matteis A, Di Costanzo F, Passalacqua R, et al. Patterns of relapse and modalities of treatment of breast cancer: the ‘IRIS’ project, a multicenter observational study. Oncology. 2004;66(4):260–8. https://doi.org/10.1159/000078325.CrossRefPubMed

22.

Kwast AB, Voogd AC, Menke-Pluijmers MB, Linn SC, Sonke GS, Kiemeney LA, et al. Prognostic factors for survival in metastatic breast cancer by hormone receptor status. Breast Cancer Res Treat. 2014;145(2):503–11. https://doi.org/10.1007/s10549-014-2964-0.CrossRefPubMed

23.

Giordano SH, Buzdar AU, Smith TL, Kau SW, Yang Y, Hortobagyi GN. Is breast cancer survival improving? Cancer. 2004;100(1):44–52. https://doi.org/10.1002/cncr.11859.CrossRefPubMed

24.

Wyld L, Gutteridge E, Pinder SE, James JJ, Chan SY, Cheung KL, et al. Prognostic factors for patients with hepatic metastases from breast cancer. Br J Cancer. 2003;89(2):284–90. https://doi.org/10.1038/sj.bjc.6601038.CrossRefPubMedPubMedCentral

25.

Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand—binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol. 1999;17(5):1474–81. https://doi.org/10.1200/JCO.1999.17.5.1474.CrossRefPubMed

26.

Regierer AC, Wolters R, Ufen MP, Weigel A, Novopashenny I, Köhne CH, et al. An internally and externally validated prognostic score for metastatic breast cancer: analysis of 2269 patients. Ann Oncol. 2014;25(3):633–8. https://doi.org/10.1093/annonc/mdt539.CrossRefPubMed

27.

Newton PK, Mason J, Venkatappa N, Jochelson MS, Hurt B, Nieva J, et al. Spatiotemporal progression of metastatic breast cancer: a Markov chain model highlighting the role of early metastatic sites. NPJ Breast Cancer. 2015;1(1):15018. https://doi.org/10.1038/npjbcancer.2015.18.CrossRefPubMedPubMedCentral

28.

Onken JS, Fekonja LS, Wehowsky R, Hubertus V, Vajkoczy P. Metastatic dissemination patterns of different primary tumors to the spine and other bones. Clin Exp Metastasis. 2019. https://doi.org/10.1007/s10585-019-09987-w.

29.

Kennecke H, Yerushalmi R, Woods R, Cheang MC, Voduc D, Speers CH, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010;28(20):3271–7. https://doi.org/10.1200/JCO.2009.25.9820.CrossRef

30.

Kast K, Link T, Friedrich K, Petzold A, Niedostatek A, Schoffer O, et al. Impact of breast cancer subtypes and patterns of metastasis on outcome. Breast Cancer Res Treat. 2015;150(3):621–9. https://doi.org/10.1007/s10549-015-3341-3.CrossRefPubMed

31.

Turner NC, Finn RS, Martin M, Im SA, DeMichele A, Ettl J, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29(3):669–80. https://doi.org/10.1093/annonc/mdx797.CrossRefPubMedPubMedCentral

Title: New insights into patterns of first metastatic sites influencing survival of patients with hormone receptor-positive, HER2-negative breast cancer: a multicenter study of 271 patients
Authors: Jun Yamamura
Shunji Kamigaki
Junya Fujita
Hiroki Osato
Hironobu Manabe
Yumiko Tanaka
Wataru Shinzaki
Yukihiko Hashimoto
Yoshifumi Komoike
Publication date: 01-12-2021
Publisher: BioMed Central
Keywords: Metastasis
Breast Cancer
Breast Cancer
Published in: BMC Cancer / Issue 1/2021
Electronic ISSN: 1471-2407
DOI: https://doi.org/10.1186/s12885-021-08219-3

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2021

Computational analysis for identification of early diagnostic biomarkers and prognostic biomarkers of liver cancer based on GEO and TCGA databases and studies on pathways and biological functions affecting the survival time of liver cancer

Colorectal cancer survival among Ministry of National Guard-Health Affairs (MNG-HA) population 2009–2017: retrospective study

Neuroblastoma xenograft models demonstrate the therapeutic potential of 177Lu-octreotate

Analytical validation of the Percepta genomic sequencing classifier; an RNA next generation sequencing assay for the assessment of Lung Cancer risk of suspicious pulmonary nodules

Influence of migrant background on patient preference and expectations in breast and gynecological malignancies (NOGGO-expression V study): results of a prospective multicentre study in 606 patients in Germany

Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer